
|Videos|November 15, 2017
Dr. Postow on Entrectinib in Melanoma
Author(s)Michael A. Postow, MD
Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of entrectinib for patients with NTRK fusion-positive melanoma.
Advertisement
Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of entrectinib for patients with NTRK fusion-positive melanoma.
Following more comprehensive molecular profiling, there are different genetic fusion events or other types of activating mutations, states Postow. There is a new fusion that has been discovered around NTRK that affects patients with advanced melanoma.
There are some promising strategies being used to target NTRK fusion, such as entrectinib, Postow explains.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5




































